相关实验视频
Updated: Jan 16, 2026

11:21
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
20.1K
系统审查和元分析:手术性心脏消血是否有效预防手术后心房动?
Danyal Bakht1, Maaz Amir1, Fahad Saleem2
1Department of Medicine, King Edward Medical University, Lahore 54000, Punjab, Pakistan.
World journal of cardiology
|September 30, 2025
概括
手术心脏变色并没有减少整体术后心房动 (POAF),但显著降低了持久性POAF的发生率. 这种程序还降低了血清水平,但没有影响其他主要的临床结果.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 电子生理学 电子生理学
背景情况:
- 手术后心房动 (POAF) 是心脏手术后的常见并发症,增加了发病率和住院时间.
- 通过减少心脏自主输入,作为POAF的预防策略,正在探索手术心脏缩.
- 目前关于手术心脏消血在预防POAF的有效性的证据是不一致的.
研究的目的:
- 进行一项元分析,评估手术心脏消血对POAF发病率的影响.
- 评估手术性心脏化对心脏手术后相关临床结果的影响.
主要方法:
- 根据PRISMA指南进行的元分析,搜索PubMed,Cochrane,ScienceDirect和EMBASE,截至2025年4月.
- 使用ROBIS和ROB 2.0工具进行偏差风险评估.
- 使用Review Manager 5.4进行数据分析,通过I2统计和固定/随机效应模型评估异质性.
主要成果:
- 包括五项研究 (N=1266);627名患者患有心脏缺血,639名作为对照.
- 手术心脏消皮没有显著减少整体POAF (OR=0.71,P=0.40,I2=83%).
- 观察到持续性心房的显著减少 (OR=0.19,P<0.00001,I2=0%),随着手术后血清水平的降低 (MD=-0.07 mmol/L,P<0.00001).
结论:
- 手术性心脏缩并没有显著降低术后心房的总体发病率.
- 该程序有效地降低了持续性心房的发生率.
- 在诸如中风,出血再手术,住院或死亡等结果中没有发现显著差异.
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
287
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
287
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Dysrhythmias VI: Management of Dysrhythmias
432
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
432
Aortic Regurgitation III: Medical Management
397
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
397

